Chemoinformaics analysis of 2,2,5-Trimethyl-4-cyclohepten-1-one
| Molecular Weight | 152.237 | nRot | 0 |
| Heavy Atom Molecular Weight | 136.109 | nRig | 8 |
| Exact Molecular Weight | 152.12 | nRing | 1 |
| Solubility: LogS | -2.216 | nHRing | 0 |
| Solubility: LogP | 2.557 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 27 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 11 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 16 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 10 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 28.1707 |
| nHD | 0 | BPOL | 16.9193 |
| QED | 0.488 |
| Synth | 2.979 |
| Natural Product Likeliness | 2.295 |
| NR-PPAR-gamma | 0.007 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.065 |
| Pgp-sub | 0.001 |
| HIA | 0.003 |
| CACO-2 | -4.482 |
| MDCK | 0.0000222 |
| BBB | 0.923 |
| PPB | 0.846029 |
| VDSS | 1.583 |
| FU | 0.250684 |
| CYP1A2-inh | 0.362 |
| CYP1A2-sub | 0.799 |
| CYP2c19-inh | 0.26 |
| CYP2c19-sub | 0.909 |
| CYP2c9-inh | 0.064 |
| CYP2c9-sub | 0.937 |
| CYP2d6-inh | 0.011 |
| CYP2d6-sub | 0.699 |
| CYP3a4-inh | 0.024 |
| CYP3a4-sub | 0.199 |
| CL | 9.239 |
| T12 | 0.821 |
| hERG | 0.011 |
| Ames | 0.113 |
| ROA | 0.439 |
| SkinSen | 0.193 |
| Carcinogencity | 0.923 |
| EI | 0.909 |
| Respiratory | 0.726 |
| NR-Aromatase | 0.009 |
| Antiviral | No |
| Prediction | 0.91233 |